CRSwNP Advances: How Biologics are Transforming Treatment

In recent years, biologics have revolutionised the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) — delivering outcomes once thought impossible. By targeting the type 2 inflammatory cascade that drives CRSwNP, biologics offer a true paradigm shift in patient care. Most biologics act on key mediators, such as IL-4/IL-13, IL-5, and IgE, directly addressing the root cause of the disease.

Over the past 5 years, three biologics have been approved and reimbursed in many countries:

• Omalizumab
• Mepolizumab
• Dupilumab

These therapies have demonstrated proven efficacy, a strong safety profile, and even superiority over repeat surgery in severe, uncontrolled cases. For patients, this means fewer surgeries. For clinicians, it means more pathways to remission.

To tell us more about these two promising novel molecules for CRSwNP, EUFOREA invited Prof. Joseph Han (Professor in Otorhinolaryngology, Head and Neck Surgery at Eastern Virginia Medical School, USA, Vice Chair of Clinical Affairs and Administration and Chief of the Division of Allergy) and Prof. Jivianne Lee (Associate Professor of Rhinology & Endoscopic Skull Base Surgery, Head and Neck Surgery at the University of California, USA).